This article was originally published here
Transl Behav Med. 2021 May 8: ibab054. doi: 10.1093 / tbm / ibab054. Online before printing.
Limited research has reported the commercial feasibility of efforts to attract and involve a target audience in evidence-based approaches to disease prevention – from both a research and a practical perspective. We wanted to retrospectively assess and estimate the cost of a population health management (PHM) approach to identify, enroll and include patients in a type 1 diabetes prevention study with type 1 hybrid effectiveness implementation (HEI). We used activity-based cost accounting to estimate the cost of recruiting a PHM approach built into a university study. We have taken the perspective of a health system that can adopt and possibly maintain the strategy in typical practice. We also estimated the cost of replication based on how the strategy might be applied in healthcare systems interested in referring patients to a local diabetes prevention program from a payer perspective. The total enrollment and enrollment costs were $ 360,424 to reach 599 attendees over a period of approximately 15 months. The average cost per participant reviewed and enrolled was $ 263 and $ 620, respectively. In typical settings, the total cost of recruiting for replication was estimated at $ 193,971 (range: $ 43,827 – $ 210,721). The results of the sensitivity and scenario analysis indicated that if glucose testing were required, the cost of replication would be approximately $ 283 to $ 444 per enrolled patient, based on the services covered by Medicare. From the perspective of private payers and without a glucose test, the estimated cost per participant was estimated at USD 31. A PHM approach can be used to attract large numbers of participants to an HEI study in a short period of time at a comparable cost per participant.
PMID: 33963855 | DOI: 10.1093 / tbm / ibab054